Bio-Techne Surges as Merck Agrees to Acquire Company at $73 Per Share in Cash

Market Focus06-25 22:27

On June 25, Bio-Techne surges over 19% in intraday trading. The move was triggered by news that Merck KGaA Group has agreed to acquire Bio-Techne at $73 per share in an all-cash transaction.

The acquisition comes after activist investor Ananym Capital Management had sent a letter to Bio-Techne's board urging a strategic review, including a potential sale to a larger industry player. Ananym argued that a sale would deliver more value than Bio-Techne could achieve as a standalone company. The $73 per share offer represents a substantial premium to the analyst consensus price target of $61.42 and the stock's prior trading level near $59.45.

Bio-Techne's attractiveness as an acquisition target was further supported by its strategic positioning in cell therapy through a planned full acquisition of Wilson Wolf, its Ella platform receiving EU CE-IVD certification, and its broad portfolio of life science reagents, instruments, and services serving global research, diagnostics, and bioprocessing markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

6

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107820276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107820276","market":"us","top_or_hot":-1,"title":"Bio-Techne Surges as Merck Agrees to Acquire Company at $73 Per Share in Cash","media":"Market Focus","content":"<html><head></head><body><p style=\"text-align: left;\">On June 25, <a href=\"https://laohu8.com/S/TECH\">Bio-Techne</a> surges over 19% in intraday trading. The move was triggered by news that Merck KGaA Group has agreed to acquire Bio-Techne at $73 per share in an all-cash transaction.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/33cc1a5028a0422ff891dcb05c45e388\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p><p style=\"text-align: left;\">The acquisition comes after activist investor Ananym Capital Management had sent a letter to Bio-Techne&#39;s board urging a strategic review, including a potential sale to a larger industry player. Ananym argued that a sale would deliver more value than Bio-Techne could achieve as a standalone company. The $73 per share offer represents a substantial premium to the analyst consensus price target of $61.42 and the stock&#39;s prior trading level near $59.45.</p><p style=\"text-align: left;\">Bio-Techne&#39;s attractiveness as an acquisition target was further supported by its strategic positioning in cell therapy through a planned full acquisition of Wilson Wolf, its Ella platform receiving EU CE-IVD certification, and its broad portfolio of life science reagents, instruments, and services serving global research, diagnostics, and bioprocessing markets.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p><p style=\"text-align: left;\"></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne Surges as Merck Agrees to Acquire Company at $73 Per Share in Cash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne Surges as Merck Agrees to Acquire Company at $73 Per Share in Cash\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 22:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">On June 25, <a href=\"https://laohu8.com/S/TECH\">Bio-Techne</a> surges over 19% in intraday trading. The move was triggered by news that Merck KGaA Group has agreed to acquire Bio-Techne at $73 per share in an all-cash transaction.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/33cc1a5028a0422ff891dcb05c45e388\" data-align=\"center\" data-image-type=\"kline\" tg-width=\"560\" tg-height=\"240\"/><span></span></p><p style=\"text-align: left;\">The acquisition comes after activist investor Ananym Capital Management had sent a letter to Bio-Techne&#39;s board urging a strategic review, including a potential sale to a larger industry player. Ananym argued that a sale would deliver more value than Bio-Techne could achieve as a standalone company. The $73 per share offer represents a substantial premium to the analyst consensus price target of $61.42 and the stock&#39;s prior trading level near $59.45.</p><p style=\"text-align: left;\">Bio-Techne&#39;s attractiveness as an acquisition target was further supported by its strategic positioning in cell therapy through a planned full acquisition of Wilson Wolf, its Ella platform receiving EU CE-IVD certification, and its broad portfolio of life science reagents, instruments, and services serving global research, diagnostics, and bioprocessing markets.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p><p style=\"text-align: left;\"></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"","article_id":"1107820276","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107820276","pubTimestamp":1782397621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Bio-Techne surged 22.23% in pre-market trading, trading at approximately $72.15 per share. The move was triggered by news that Merck KGaA Group has agreed to acquire Bio-Techne at $73 per...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation","MRK":"默沙东"},"translate_title":"默克同意以每股73美元现金收购公司，Bio-Techne股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/577360835da8ac82baa77097e6a2529a","symbols_score_info":{"TECH":2.1,"MRK":2},"content_text":"On June 25, Bio-Techne surges over 19% in intraday trading. The move was triggered by news that Merck KGaA Group has agreed to acquire Bio-Techne at $73 per share in an all-cash transaction.The acquisition comes after activist investor Ananym Capital Management had sent a letter to Bio-Techne's board urging a strategic review, including a potential sale to a larger industry player. Ananym argued that a sale would deliver more value than Bio-Techne could achieve as a standalone company. The $73 per share offer represents a substantial premium to the analyst consensus price target of $61.42 and the stock's prior trading level near $59.45.Bio-Techne's attractiveness as an acquisition target was further supported by its strategic positioning in cell therapy through a planned full acquisition of Wilson Wolf, its Ella platform receiving EU CE-IVD certification, and its broad portfolio of life science reagents, instruments, and services serving global research, diagnostics, and bioprocessing markets.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"merge,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":6,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107820276","isCrawlerRequest":true}